Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Non-Hodgkin 12Lymphoma 12Recurrence 11Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia 9Leukemia, Biphenotypic, Acute 8Ovarian Neoplasms 7Neoplasms 7Lymphoma, Mantle-Cell 7Myeloproliferative Disorders 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 6Hodgkin Disease 6Hematologic Neoplasms 6Lymphoma, Follicular 5Immunoproliferative Disorders 5Immune System Diseases 5Lymphoproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Lymphatic Diseases 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Mesothelioma 3Lung Neoplasms 3

Interventions

fludarabine 1Radiation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liposarcoma, Myxoid × fludarabine × Clear all
NCT03967223 2026-04-17

IGNYTE-ESO

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
103 enrolled
Sarcoma

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡